《美股业绩》强生季绩胜预期 疫苗加警告标签後重新在欧洲推出
强生(JNJ.US)首季盈利增长6.9%至61.97亿美元,收入上升7.9%至223.2亿美元,两者皆优於预期。强生将调整後的全年每股盈利指引由9.4至9.6美元,修订至9.42至9.57美元。
欧洲药品管理局(EMA)表示,强生疫苗或与血栓塞有关,但认为疫苗作用利大於弊,建议在疫苗标签上添加有关会造成血栓塞的警告字句,强生表示将继续在欧洲推出疫苗。
强生称,新的包装标签将包括对罕见副作用的风险警告,以及如何识别及治疗该副作用的,将重新开始向欧盟、挪威及冰岛运送疫苗,并重启临床测试。
美国疾控制中心及美国食品及药物管理局(FDA)亦在审查强生疫苗,预计周五会议後会有结果。强生表示,将履行承诺分别向欧洲及美国运送2亿及1亿剂疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.